IBB241122C190000
- 0.00
- 0.000.00%
iShares Biotechnology ETF Newsroom
Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR
Sector Update: Health Care Stocks Advance Pre-Bell Friday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of US Farm Prices Data
Wednesday Ends With Index Decline | Wall Street Today
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Regeneron Pharmaceuticals Unusual Options Activity
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122
BioNTech Analyst Ratings